<p><i><strong>Prior Phase 3 studies showed positive benefits in increasing unstimulated whole saliva secretion Ainos aims to complete all regulatory approvals for the study in Q4 2024</strong></i></p>

<p><i><strong>Ainos Plans To Conduct the Study at National Taiwan University Hospital, a Premier Taiwanese Medical Center for HIV Management</strong></i></p><p><i><strong>The U.S. FDA Have Granted Orphan Drug Designation (ODD) for the Company's VELDONA^&reg; Low-Dose Oral Interferon Formulation as a Potential Treatment for Oral Warts in HIV-Positive Patients</strong></i></p>